RVMD:NSD-Revolution Medicines Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 37.95

Change

0.00 (0.00)%

Market Cap

USD 6.15B

Volume

0.81M

Analyst Target

USD 42.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 110.51B
MRNA Moderna Inc

N/A

USD 57.87B
BNTX BioNTech SE

N/A

USD 24.18B
ARGX argenx NV ADR

N/A

USD 23.04B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 20.29B
GMAB Genmab AS

N/A

USD 18.17B
BGNE BeiGene Ltd

N/A

USD 17.74B
RPRX Royalty Pharma Plc

N/A

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.32B

ETFs Containing RVMD

XDNA:CA iShares Genomics Immunolo.. 5.72 % 0.00 %

N/A

CAD 5.15M
XBI SPDR® S&P Biotech ETF 1.32 % 0.35 %

N/A

USD 7.07B
CURE:AU ETFS S&P Biotech ETF 1.29 % 0.00 %

N/A

USD 0.04B
LABU Direxion Daily S&P Biotec.. 0.78 % 1.14 %

N/A

USD 1.10B
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

N/A

USD 0.02B
IDNA iShares Genomics Immunolo.. 0.00 % 0.00 %

N/A

USD 0.14B
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

N/A

USD 0.10B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 32.32% 78% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.32% 78% C+ 86% B+
Trailing 12 Months  
Capital Gain 48.18% 84% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.18% 84% B 87% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.65% 61% D- 53% F
Dividend Return 2.65% 61% D- 49% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.63% 75% C 53% F
Risk Adjusted Return 7.65% 67% D+ 47% F
Market Capitalization 6.15B 96% N/A 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector